Do genetic factors protect against Parkinson's disease? What I can learn from my healthy grandma.

Parkinson's disease (PD) is a progressive, neurodegenerative disorder and it affects 4-5% of people age 85 years or older. The etiopathogenesis of PD is a consequence of interaction between two factors, environmental pathogens and genetic susceptibility. If an environmental agent such as a toxin or pathogen were to play a major role in the causality of PD, it would need to be something relatively ubiquitous in our environment since we cannot find a specific population at risk. On the other hand, all efforts to implicate specific genetic sequences in risk of PD were futile since the great majority of PD cases are sporadic; however, if the majority of the population is exposed to a culpable environmental factor and only 5% of the population 85 years or older manifest the disorder, this raises an important question: Why and how does vast majority of the population not manifest with PD? It seems that we should investigate the certain genome or epigenetic alterations of the unaffected 95%. This large non affected population might have PD but they are not yet symptomatic and some may not be so for at least another 10 or 20 years. To further address this issue, we should screen and study the population that have been exposed to the environmental factor but with high certainty are not yet affected. Therefore the perfect population would be non-PD subjects who are 90 years or older. We believe the following are the unmet research needs that deserve more attention in PD. (1) More genetic studies. Comparison should be between PD subjects and non-PD control subjects who are 90 years old and above. (2) Study the mechanism of action of the candidate genes, as a subsequent examination of their gene products may lead to the discovery of neuroprotective agents in the disease.

[1]  Sonja W. Scholz,et al.  Genome-Wide Association Study reveals genetic risk underlying Parkinson’s disease , 2009, Nature Genetics.

[2]  Mohamad Saad,et al.  Imputation of sequence variants for identification of genetic risks for Parkinson's disease: a meta-analysis of genome-wide association studies , 2011, The Lancet.

[3]  Simon C. Potter,et al.  A Two-Stage Meta-Analysis Identifies Several New Loci for Parkinson's Disease , 2011, PLoS genetics.

[4]  S. Tsuji,et al.  CpG Demethylation Enhances Alpha-Synuclein Expression and Affects the Pathogenesis of Parkinson's Disease , 2010, PloS one.

[5]  Nicholas Eriksson,et al.  Web-Based Genome-Wide Association Study Identifies Two Novel Loci and a Substantial Genetic Component for Parkinson's Disease , 2011, PLoS genetics.

[6]  Paola Sebastiani,et al.  The Genetics of Extreme Longevity: Lessons from the New England Centenarian Study , 2012, Front. Gene..

[7]  C. Olanow,et al.  Parkinson's Disease and Alpha Synuclein: Is Parkinson's Disease a Prion‐Like Disorder? , 2013, Movement disorders : official journal of the Movement Disorder Society.

[8]  R. Uitti,et al.  Autosomal dominant Parkinson's disease. , 2012, Parkinsonism & related disorders.

[9]  E. Masliah,et al.  Alpha-synuclein sequesters Dnmt1 from the nucleus: a novel mechanism for epigenetic alterations in Lewy body diseases. , 2011, The Journal of biological chemistry.

[10]  S. Factor,et al.  A genetic basis for the variable effect of smoking/nicotine on Parkinson's disease , 2012, The Pharmacogenomics Journal.

[11]  Mariza de Andrade,et al.  High-resolution whole-genome association study of Parkinson disease. , 2005, American journal of human genetics.

[12]  N. Volkow,et al.  DRD4 Genotype Predicts Longevity in Mouse and Human , 2013, The Journal of Neuroscience.

[13]  A. Surguchov Synucleins: Are they two‐edged swords? , 2013, Journal of neuroscience research.

[14]  K. Shannon,et al.  Alpha‐synuclein in colonic submucosa in early untreated Parkinson's disease , 2012, Movement disorders : official journal of the Movement Disorder Society.

[15]  R. Hauser,et al.  Lewy body–like pathology in long-term embryonic nigral transplants in Parkinson's disease , 2008, Nature Medicine.

[16]  Montgomery Slatkin,et al.  Epigenetic Inheritance and the Missing Heritability Problem , 2009, Genetics.

[17]  Mohamad Saad,et al.  Genome-wide association study confirms BST1 and suggests a locus on 12q24 as the risk loci for Parkinson's disease in the European population. , 2011, Human molecular genetics.

[18]  Oliver Kaut,et al.  Methylation Regulates Alpha-Synuclein Expression and Is Decreased in Parkinson's Disease Patients' Brains , 2010, The Journal of Neuroscience.

[19]  T. Dall,et al.  The current and projected economic burden of Parkinson's disease in the United States , 2013, Movement disorders : official journal of the Movement Disorder Society.

[20]  C. Kawas The oldest old and the 90+ Study , 2008, Alzheimer's & Dementia.

[21]  Masato Hasegawa,et al.  Prion-like spreading of pathological α-synuclein in brain , 2013, Brain : a journal of neurology.

[22]  Paola Sebastiani,et al.  Genome-Wide Association Studies (GWAS) , 2019, Definitions.

[23]  H. Adami,et al.  Epidemiology and etiology of Parkinson’s disease: a review of the evidence , 2011, European Journal of Epidemiology.

[24]  A. Bentivoglio,et al.  Epidemiological, Clinical, and Molecular Study of a Cohort of Italian Parkinson Disease Patients: Association with Glutathione-S-Transferase and DNA Repair Gene Polymorphisms , 2013, Cellular and Molecular Neurobiology.

[25]  Yuet-Kin Leung,et al.  Environmental epigenetics and its implication on disease risk and health outcomes. , 2012, ILAR journal.

[26]  G. Lopez,et al.  Autosomal recessive mutations in the development of Parkinson's disease. , 2010, Biomarkers in medicine.

[27]  Manel Esteller,et al.  Epigenetic mechanisms in neurological diseases: genes, syndromes, and therapies , 2009, The Lancet Neurology.

[28]  I. Martin,et al.  Recent advances in the genetics of Parkinson's disease. , 2011, Annual review of genomics and human genetics.